Rhode Island Chronicle

Alzheimer’s Disease Pipeline Landscape Analysis of 100+ Companies by DelveInsight

 Breaking News
  • No posts were found

Alzheimer’s Disease Pipeline Landscape Analysis of 100+ Companies by DelveInsight

October 04
19:28 2022
Alzheimer’s Disease Pipeline Landscape Analysis of 100+ Companies by DelveInsight

DelveInsight’s, “Alzheimer’s Disease Pipeline Insights, 2022,” report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Alzheimer’s Disease (AD) pipeline landscape.

 

DelveInsight’s “Alzheimer’s Disease Pipeline Insight” report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in the Alzheimer’s Disease pipeline landscapes. It comprises Alzheimer’s Disease pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Alzheimer’s Disease therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Alzheimer’s Disease pipeline products.    

Key takeaways of the Alzheimer’s Disease Pipeline Report 

  • DelveInsight’s Alzheimer’s Disease Pipeline report depicts a robust space with 100+ active players working to develop 100+ pipeline therapies for various indications.
  • Leading companies such as Eisai, Biogen, Changchun Huayang High-tech Co. Ltd., Hoffmann-La Roche, vTv Therapeutics, AZTherapies, Cerecin, Neurotrope, Lyndra, AC Immune, INmune Bio, Cassava Sciences, EIP Pharma, Neuraly, AB Science, Cortexyme, Anavex Life Sciences, Athira Pharma, Time Therapeutics, Prilenia Therapeutics, Denali Therapeutics Inc., and others are developing potential drug candidates to boost the Alzheimer’s Disease treatment scenario.
  • The Promising Alzheimer’s Disease therapies such as BAN2401, Gantenerumab, and others

 

Request a sample and discover the recent advances in Alzheimer’s Disease @ Alzheimer’s Disease Pipeline Outlook

 

Alzheimer’s Disease Overview

Alzheimer’s Disease (AD) is a slowly progressive brain disease that begins many years before symptoms emerge. It is the most common cause of dementia, accounting for an estimated 60% to 80% of cases. The hallmark pathologies of Alzheimer’s disease are the accumulation of the protein fragment beta‐amyloid (plaques) outside neurons in the brain and twisted strands of the protein tau (tangles) inside neurons. These changes are accompanied by the death of neurons and damage to brain tissue. On the basis of severity, this degenerative disease can be classified as mild, moderate, and severe.

Latest Breakthroughs and Developments in the Alzheimer’s Disease Treatment Landscape

  • In February 2021, NeurMedix announced that it had received authorization from the U.S. Food and Drug Administration’s (FDA) Office of Neuroscience, Division of Neurology I, to initiate a pivotal phase 3 clinical trial in Alzheimer’s Disease with its lead clinical drug candidate, NE3107.
  • In December 2019, BioArctic declared the initiation of a research deal with Eisai to investigate further the unique profile of the investigational drug candidate BAN2401.
  • In June 2020, Eli Lilly and Company initiated TRAILBLAZER-ALZ 2, a Phase III clinical study of Donanemab for the treatment of Alzheimer Disease. The study is expected to be completed by December 2023, with an estimated enrollment of 1500 participants.

 

 Alzheimer’s Disease Pipeline Insight

The Alzheimer’s Disease Pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Alzheimer’s Disease, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Alzheimer’s Disease Pipeline Landscape.

 

Alzheimer’s Disease Emerging Drugs

  •  BAN2401: Eisai

BAN2401 is the humanized IgG1 version of the mouse monoclonal antibody mAb158, which selectively binds to large, soluble Aβ protofibrils. BAN2401 selectively binds to neutralize and eliminate toxic Aβ protofibrils that are thought to be a causative factor for Alzheimer’s Disease. Eisai obtained the global rights to study, develop, manufacture and market BAN2401 for the treatment of Alzheimer’s disease pursuant to an agreement concluded with BioArctic in December 2007.

  •  Gantenerumab: Hoffmann-La Roche

Gantenerumab is an investigational therapy designed to bind more specifically to aggregated forms of beta-amyloid and remove beta-amyloid plaques. Gantenerumab was originally developed by Chugai Pharmaceuticals, which is now part of Hoffmann-La Roche. This treatment is administered as an injection under the skin, is now being developed by Hoffmann-La Roche in collaboration with MorphoSys.

 

Alzheimer’s Disease Pipeline Analysis Report

  • The report provides detailed insights about emerging therapies for the Alzheimer’s Disease treatment and the aggregate therapies developed by major pharma companies.
  • It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Alzheimer’s Disease Treatment.
  • It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • The Alzheimer’s Disease Pipeline Report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Alzheimer’s Disease market.

The Alzheimer’s Disease Pipeline Report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Scope of the Alzheimer’s Disease Pipeline Report

  • Coverage- Global
  • Alzheimer’s Disease Phases- Late stage products (Phase III), Mid-stage products (Phase II), Early-stage product (Phase I) along with the details of, Pre-clinical and Discovery stage candidates, Discontinued & Inactive candidates,
  • Alzheimer’s Disease Route of Administration- Oral, Parenteral, Intravitreal, Subretinal, Topicalm,
  • Alzheimer’s Disease Molecule Type- Monoclonal Antibody, Peptides, Polymer, Small molecule, Gene therapy, Product Type
  • Alzheimer’s Disease Companies – Eisai, Biogen, Changchun Huayang High-tech Co. Ltd., Hoffmann-La Roche, vTv Therapeutics, AZTherapies, Cerecin, Neurotrope, Lyndra, AC Immune, INmune Bio, Cassava Sciences, EIP Pharma, Neuraly, AB Science, Cortexyme, Anavex Life Sciences, Athira Pharma, Time Therapeutics, Prilenia Therapeutics, Denali Therapeutics Inc, and many others
  • Alzheimer’s Disease Therapies- BAN2401, Gantenerumab, and many others

 

Dive deep into rich insights for Alzheimer’s Disease Pipeline Assessment, Visit @ Alzheimer’s Disease Pipeline Therapeutics Assessment

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Alzheimer’s Disease (AD): Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Alzheimer’s Disease (AD) – DelveInsight’s Analytical Perspective
  7. In-depth Commercial Assessment
  8. Alzheimer’s Disease (AD) Collaboration Deals
  9. Late Stage Products (Phase III)
  10. BAN2401: Eisai
  11. Mid Stage Products (Phase II)
  12. Bryostatin-1: Neurotrope
  13. Early Stage Products (Phase I)
  14. INB03 – INmune Bio
  15. Pre-clinical and Discovery Stage Products
  16. AZT-211: AZTherapies
  17. Inactive Products
  18. Alzheimer’s Disease (AD) Key Companies
  19. Alzheimer’s Disease (AD) Key Products
  20. Alzheimer’s Disease (AD)- Unmet Needs
  21. Alzheimer’s Disease (AD)- Market Drivers and Barriers
  22. Alzheimer’s Disease (AD)- Future Perspectives and Conclusion
  23. Alzheimer’s Disease (AD) Analyst Views
  24. Alzheimer’s Disease (AD) Key Companies
  25. Appendix

 

For further information on the Alzheimer’s Disease Pipeline therapeutics, reach out @ Alzheimer’s Disease Drugs

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/